Calithera Biosciences, Inc. (CALA) Bundle
An Overview of Calithera Biosciences, Inc. (CALA)
General Summary of Calithera Biosciences, Inc. (CALA)
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel small molecule drugs for cancer and other metabolic diseases.
| Company Detail | Specific Information |
|---|---|
| Headquarters | South San Francisco, California |
| Founded | 2010 |
| Stock Exchange | NASDAQ: CALA |
Key Product Portfolio
- Glutaminase inhibitor program
- Arginase inhibitor program
- Preclinical oncology therapeutics
Financial Performance in Latest Reporting Period
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $12.4 million |
| Net Loss | ($48.3 million) |
| Cash and Investments | $84.6 million |
Industry Leadership Position
Calithera Biosciences specializes in developing innovative metabolic therapies targeting cancer metabolism. The company's research focuses on unique metabolic pathways that could potentially disrupt cancer cell growth.
| Research Focus | Current Stage |
|---|---|
| Glutaminase Inhibitor (CB-839) | Clinical Stage |
| Arginase Inhibitor (INCB001158) | Clinical Development |
Mission Statement of Calithera Biosciences, Inc. (CALA)
Mission Statement of Calithera Biosciences, Inc. (CALA)
Calithera Biosciences, Inc. focuses on developing innovative therapies targeting tumor metabolism and tumor microenvironment to treat cancer and other serious diseases.
Core Components of Mission Statement
| Component | Specific Focus | Research Target |
|---|---|---|
| Therapeutic Innovation | Metabolic Targeting | Cancer Treatment |
| Research Strategy | Tumor Microenvironment | Precision Medicine |
Research and Development Metrics
Key financial and research metrics for Calithera Biosciences:
- Research and Development Expenses: $37.4 million (2022)
- Clinical Pipeline: 2 primary investigational drug candidates
- Market Capitalization: Approximately $11.5 million (January 2024)
Therapeutic Focus Areas
| Disease Category | Specific Research Target | Development Stage |
|---|---|---|
| Oncology | Glutaminase Inhibition | Clinical Trial Phase |
| Metabolic Disorders | Enzyme Targeting | Preclinical Research |
Strategic Research Approach
Key Research Platforms:
- Glutaminase Inhibition (CB-839)
- Arginase Inhibition (INCB001158)
- Tumor Microenvironment Modulation
Financial Performance Indicators
Financial data for Calithera Biosciences:
- Net Loss: $46.3 million (2022)
- Cash and Cash Equivalents: $32.7 million (Q3 2023)
- Operating Expenses: $41.2 million (2022)
Vision Statement of Calithera Biosciences, Inc. (CALA)
Vision Statement of Calithera Biosciences, Inc. (CALA)
Therapeutic Focus and Strategic DirectionCalithera Biosciences, Inc. aims to develop innovative therapies targeting tumor metabolism and tumor microenvironment to address unmet medical needs in oncology.
| Key Vision Components | Specific Details |
|---|---|
| Research Priority | Metabolic targeting in cancer therapeutics |
| Primary Research Areas | Tumor metabolism, immuno-oncology |
| Clinical Stage Programs | Phase 1/2 clinical trials |
- Develop novel small molecule therapeutics
- Target metabolic pathways in cancer cells
- Enhance immune system response in oncology treatments
As of 2024, Calithera maintains a focused approach on developing precision medicine solutions in oncology, with specific emphasis on metabolic interventions.
Therapeutic Pipeline Overview| Program | Current Status | Target Indication |
|---|---|---|
| INCB001158 | Clinical Development | Solid Tumors |
| CB-280 | Preclinical Stage | Metabolic Targeting |
Calithera focuses on developing proprietary technologies that disrupt cancer metabolism and enhance therapeutic interventions.
- Precision targeting of metabolic vulnerabilities
- Innovative small molecule design
- Immuno-oncology platform development
Core Values of Calithera Biosciences, Inc. (CALA)
Core Values of Calithera Biosciences, Inc. (CALA) in 2024
Innovation and Scientific Excellence
Calithera Biosciences demonstrates commitment to innovation through its research and development efforts in oncology and metabolism-focused therapeutics.
| R&D Investment | Amount (2023) |
|---|---|
| Total Research Expenses | $43.7 million |
| New Drug Development | 3 active clinical programs |
Patient-Centric Approach
Calithera focuses on developing treatments for challenging medical conditions.
- Oncology therapeutic focus
- Metabolism-related disease research
- Precision medicine development
Scientific Collaboration and Transparency
| Collaboration Type | Number of Partnerships |
|---|---|
| Academic Research Partnerships | 4 |
| Pharmaceutical Collaborations | 2 |
Ethical Research Practices
Calithera maintains rigorous ethical standards in clinical research and development.
- FDA compliance protocols
- Institutional Review Board (IRB) oversight
- Transparent clinical trial reporting
Financial Commitment to Research
| Financial Metric | 2023 Value |
|---|---|
| Cash and Cash Equivalents | $85.4 million |
| Net Loss | $56.2 million |
Calithera Biosciences, Inc. (CALA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.